(Total Views: 510)
Posted On: 01/13/2021 2:15:03 AM
Post# of 145247
Quote:
That means that 10% of all patients have significantly less CCR5 molecules. So if CCR5 blockade works in covid, it works significantly better in CCR5delta32 heterozygous mutants.
That 10% single allele is of those who have European heritage. The double allele in that population is 1%. I would guess in the American population single allele would be around 8%. Which would work out to 20 patients in the leronlimab arm. Too small of a population to draw any firm conclusions.
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)